|
|
|
| Effects of Sintilimab Combined with Chemotherapy on Short-Term Efficacy and Serum CEA, sTim-3 sLAG-3 and T Lymphocyte Subsets in Patients with Advanced Gastric Cancer |
| LIU Zhao, REN Yuchuan, ZHANG Yapeng, et al |
| Yangquan First People' s Hospital, Shanxi Yangquan 045000, China |
|
|
|
|
Abstract Objective: To investigate the effects of Sintilimab combined with chemotherapy on short-term efficacy and serum carcinoembryonic antigen (CEA), immune function, and T lymphocyte subsets in patients with advanced gastric cancer. Methods: A total of 84 patients with advanced gastric cancer treated from May 2020 to May 2022 were randomly divided into an observation group and a control group (42 cases each). The control group received conventional chemotherapy, while the observation group received additional Sintilimab. Both groups underwent three cycles of continuous treatment (3 months). Clinical outcomes after 1 month of chemotherapy, occurrence of toxicities, and changes in serum tumor markers (CA, CEA, MG-Ag), immune function (sTim-3, sLAG-3), and T lymphocyte subsets (CD3+, CD4+, CD8+) were compared between the two groups before and after 3 cycles of treatment. The 1-year survival rate was recorded during follow-up. Results: After 1 month of chemotherapy, the observation group showed a higher clinical effective rate compared to the control group, with no significant differences in toxicities (P>0.05). After 3 cycles of treatment, both groups exhibited significant reductions in CA, CEA, MG-Ag, sTim-3, and sLAG-3 levels, and the observation group had lower levels than the control group (all P<0.05), CD3+ and CD4+ levels decreased, with the observation group higher than the control group, while CD8+ levels increased, and the observation group had lower levels than the control group (all P<0.05). The 1-year survival rate in the observation group was significantly higher than in the control group (P<0.05). Conclusion: Sintilimab combined with chemotherapy demonstrates significant short-term efficacy, high safety, and the ability to improve immune function in patients with advanced gastric cancer, thereby alleviating the tumor burden.
|
|
|
|
|
|
[1] 陆俊,许斌斌,沈莉莉,等.2000年至2019年胃癌随机对照试验特性与趋势分析[J].中华外科杂志,2022,60(5):478-485.
[2] Wang JP,Du JL,Li Y.Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer[J].World journal of gastrointestinal oncology,2023,15(1):143-154.
[3] 姜志超.晚期胃癌一线免疫治疗的现状与进展[J].中国肿瘤临床,2023,50(4):206-211.
[4] Ryosuke H,Mami H,Yuichi S,et al.Feasibility of endoscopic evaluation of Helicobacter pylori infection status by using the Kyoto classification of gastritis in the population-based gastric cancer screening program:a prospective cohort study[J].Health Science Reports,2021,4(3):325-329.
[5] 范珊琳,汪品秀,孔飞,等.胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J].国际肿瘤学杂志,2023,50(2):112-116.
[6] 陈博晋,胡星怡,赵菁文,等.免疫治疗在胃癌新辅助治疗中的研究进展[J].肿瘤防治研究,2022,49(7):727-732.
[7] Liu D,Shi K,Fu M,et al.Melatonin indirectly decreases gastric cancer cell proliferation and invasion via effects on cancer-associated fibroblasts[J].Life Sciences,2021,277(7):497-499.
[8] 魏晓娜,李晓辉.替加氟联合奥沙利铂治疗进展期胃癌的疗效及安全性观察[J].中国肿瘤临床与康复,2022,29(8):930-933.
[9] 宁洁,焦洋,彭万仁,等.PD-1单抗治疗晚期HER-2阴性胃癌的临床观察[J].临床肿瘤学杂志,2021,26(11):997-1003.
[10] 李琪毅,杨鹏春,晏彩华,等.T细胞免疫球蛋白黏蛋白3及BAP1,USP39与早期胃癌免疫浸润的关系[J].免疫学杂志,2023,39(2):164-170.
[11] 焦福智,陈雅蕊,姬薇,等.PD-1抑制剂联合化疗一线新辅助治疗局部进展期胃腺癌的近期疗效及安全性评估[J].中国药物警戒,2023,20(3):301-305. |
|
|
|
2024, Vol. 30 
